Matthew Menard's guest appearances

Matthew Menard

Audible Bleeding

Da Vorce Force Podcast 

Jason Lee

Jesse Cole

Greg Edwards

Tim Kurkjian

Rachel Bell

Peter Lawrence

Roger Jones

Nathan Johnson

Benjamin Starnes

Todd Rasmussen

Frank Veith

David Dulany

BRIGITTE SMITH

Brandon Crawford

Andrea Williams

OwlTail

No matter what the metrics are or what league Matt has sold in. He prides himself on selling the experience and creating life long memories through sports.--- This episode is sponsored by · Anchor: The easiest way to make a podcast.  https://anchor.fm/app

No matter what the metrics are or what league Matt has sold in. He prides himself on selling the experience and creating life long memories through sports. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. <a href="https://anchor.fm/app" rel="nofollow" target="_blank">https://anchor.fm/app</a>

Selling an Experience with Matthew Menard 

Alik Farber

Best Endovascular vs. best Surgical Therapy in patients with Critical Limb Ischemia (BEST-CLI) is a prospective, multicenter, randomized, open-label (two-arm), comparison to evaluate the effectiveness of best surgical to best endovascular revascularization in patients with CLI. Dr. Alik Farber is a Professor of Surgery and Radiology at Boston University School of Medicine and the Chief of Vascular and Endovascular Surgery at Boston Medical Center.  Dr. Matthew Menard is an Associate Professor of Surgery at Harvard Medical School and is Co-Director of Endovascular Surgery and Program Director of the vascular surgery fellowship at Brigham and Women’s Hospital. Topics Discussed  History of the trial - mentors involved, interactions with the NIH Context of the literature - limitations of the  BASIL trial Barriers to enrollment and strategies of successful institutions Choosing the endpoint of Major Adverse Limb Event (Male)-free survival Implications of cost-effectiveness component Impact of paclitaxel controversy on the trial Early lessons learned and much, much, more!!  Register here for the Big Apple Bootcamp Support Audible Bleeding Here!

<a href="http://www.bestcli.com/" rel="nofollow" target="_blank">Best Endovascular vs. best Surgical Therapy in patients with Critical Limb Ischemia (BEST-CLI)</a> is a prospective, multicenter, randomized, open-label (two-arm), comparison to evaluate the effectiveness of best surgical to best endovascular revascularization in patients with CLI. <a href="https://www.bumc.bu.edu/busm/profile/alik-farber/" rel="nofollow" target="_blank">Dr. Alik Farber</a> is a Professor of Surgery and Radiology at Boston University School of Medicine and the Chief of Vascular and Endovascular Surgery at Boston Medical Center. <a href="https://connects.catalyst.harvard.edu/Profiles/display/Person/77657" rel="nofollow" target="_blank"> Dr. Matthew Menard</a> is an Associate Professor of Surgery at Harvard Medical School and is Co-Director of Endovascular Surgery and Program Director of the vascular surgery fellowship at Brigham and Women’s Hospital. Topics Discussed <ul> <li>History of the trial - mentors involved, interactions with the NIH</li> <li>Context of the literature - limitations of the <a href="https://www.sciencedirect.com/science/article/pii/S0741521410002338?via%3Dihub" rel="nofollow" target="_blank"> BASIL trial</a></li> <li>Barriers to enrollment and strategies of successful institutions</li> <li>Choosing the endpoint of Major Adverse Limb Event (Male)-free survival</li> <li>Implications of cost-effectiveness component</li> <li>Impact of paclitaxel controversy on the trial</li> <li>Early lessons learned and much, much, more!!</li> </ul> <a href="https://surgery.weill.cornell.edu/big-apple-bootcamp-0" rel="nofollow" target="_blank">Register here for the Big Apple Bootcamp</a> <a href="https://www.audiblebleeding.com/support/" rel="nofollow" target="_blank">Support Audible Bleeding Here!</a>

BEST-CLI Discussion with Principal Investigators - Alik Farber, MD and Matthew Menard, MD